Post-earnings recap
Reported
Wed, Feb 26, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.10 per share, but did not disclose revenue figures. The stock fell by 2.20% following the earnings release, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's path forward without specific targets or revenue expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of ongoing clinical trials. They did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical programs.